Tyvaso DPI™ (inhaled treprostinil)
Tyvaso® therapeutic platform
Tyvaso DPI™ (inhaled treprostinil)
Tyvaso DPI™ is a combination drug-device product comprised of a dry powder formulation of treprostinil Inhalation Powder and a small, portable, dry powder inhaler.
The Phase 3 BREEZE study evaluated the safety and pharmacokinetics of switching PAH patients from Tyvaso® to Tyvaso DPI™ and the pivotal pharmacokinetic studies comparing Tyvaso to Tyvaso DPI have both been completed.
Our New Drug Application for Tyvaso DPI is currently pending FDA review.
Tyvaso DPI™ is an innovative technology that provides PH patients with an alternative form of inhaled treprostinil in a device that is convenient, compact, and easy to use. Tyvaso DPI is expected to reduce administration times and device maintenance.
Tyvaso DPI is an investigational combination product that is not approved for any use in any country, and the Tyvaso DPI tradename is pending FDA review.